Black Diamond's Lung Cancer Drug Shows Promising Phase 2 Results with 60% Response Rate

Black Diamond Therapeutics reported Phase 2 trial data for its lung cancer drug silevertinib, showing a 60% objective response rate and no new safety signals. The company plans to present updated results in Q2 2026 and initiate a Phase 2 trial in glioblastoma patients in H1 2026. Black Diamond's cash reserves are expected to fund operations into H2 2028. BDTX stock fell 23.77% to $2.62 on the news.